

HCONRES 324

Urging Japan to honor its commitments under the 1986 Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, and for other purposes.

Congress: 108 (2003–2005, Ended)

Chamber: House

Policy Area: International Affairs

Introduced: Nov 12, 2003

Current Status: Referred to the Subcommittee on Trade.

Latest Action: Referred to the Subcommittee on Trade. (Nov 13, 2003)

Official Text: <https://www.congress.gov/bill/108th-congress/house-concurrent-resolution/324>

Sponsor

Name: Rep. Ramstad, Jim [R-MN-3]

Party: Republican • **State:** MN • **Chamber:** House

Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Eshoo, Anna G. [D-CA-14]	D · CA		Nov 12, 2003
Rep. Brady, Kevin [R-TX-8]	R · TX		Nov 17, 2003
Rep. Hayworth, J. D. [R-AZ-5]	R · AZ		Nov 17, 2003
Rep. Tanner, John S. [D-TN-8]	D · TN		Nov 17, 2003
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Nov 20, 2003
Rep. Foley, Mark [R-FL-16]	R · FL		Nov 21, 2003
Rep. Dunn, Jennifer [R-WA-8]	R · WA		Dec 8, 2003
Rep. Frost, Martin [D-TX-24]	D · TX		Dec 8, 2003
Rep. Garrett, Scott [R-NJ-5]	R · NJ		Dec 8, 2003
Rep. John, Christopher [D-LA-7]	D · LA		Dec 8, 2003
Rep. Pitts, Joseph R. [R-PA-16]	R · PA		Dec 8, 2003
Rep. Hooley, Darlene [D-OR-5]	D · OR		Jan 21, 2004
Rep. Matheson, Jim [D-UT-2]	D · UT		Jan 21, 2004
Rep. Bilirakis, Michael [R-FL-9]	R · FL		Feb 3, 2004
Rep. Souder, Mark E. [R-IN-3]	R · IN		Feb 24, 2004

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred to	Nov 13, 2003

Subjects & Policy Tags

Policy Area:

International Affairs

Related Bills

Bill	Relationship	Last Action
108 SCONRES 80	Identical bill	Nov 10, 2003: Read twice and referred to the Committee on Foreign Relations. (text of measure as introduced: CR S14364)

Summary (as of Nov 12, 2003)

Urges Japan to honor its commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals by: (1) reducing regulatory barriers to the approval and adoption of new medical technologies; (2) establishing reasonable agency performance goals for premarket approvals and an appropriate, risk-based postmarket system consistent with globally accepted practices; (3) actively promoting pricing policies that encourage innovation; (4) implementing fair and open processes and rules that do not disproportionately harm United States medical technology products; and (5) providing opportunities for consultation with trading partners.

Actions Timeline

- **Nov 13, 2003:** Referred to the Subcommittee on Trade.
- **Nov 12, 2003:** Introduced in House
- **Nov 12, 2003:** Introduced in House
- **Nov 12, 2003:** Referred to the House Committee on Ways and Means.